ALN-HTT HDSA Presentation

ALN-HTT HDSA Presentation

In June 2011, our scientists presented an update on our Huntington’s disease program, ALN-HTT, at the 26th Annual HDSA National Convention.


 

Martin Goulet, Ph.D., Principle Scientist at Alnylam discussed our approach in developing a novel RNAi therapeutic for the treatment of Huntington’s disease, the progress we’ve made to date in our pre-clinical studies, and expected next steps in development.  Ken Serbin, author of the blog, At Risk for Huntington’s Disease, was also awarded Person of the Year at this convention for his advocacy efforts within the Huntington’s Disease community, and his unwavering commitment to increase awareness of the disease.



SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.